Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 267

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 267
---
 |    -1,616 | ​ |   |    -5,847 |
| Net loss                                                                                                   | ​ | $                                    |  -891,382 | ​ | $ |  -858,231 |
| ​                                                                                                          | ​ | ​                                    |         ​ | ​ | ​ |         ​ |
| ​                                                                                                          | ​ | ​                                    |         ​ | ​ | ​ |         ​ |
| Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption | ​ |                                      | 7,055,859 | ​ |   | 7,275,074 |
| ​                                                                                                          | ​ | ​                                    |         ​ | ​ | ​ |         ​ |
| Basic and diluted net loss per share, Class A common stock subject to possible redemption                  | ​ | $                                    |     -0.13 | ​ | $ |     -0.12 |

The accompanying notes are an integral part of these unaudited condensed financial statements.

F-54

IRIS ACQUISITION CORP CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT (UNAUDITED)

| ​                                                                     
 ​                                                                     
 ​                                                                     
 ​                                                                     
 ​                                                                     | ​ 
 ​ 
 ​ 
 ​ |            ​ 
 Common Stock 
      Class A 
            ​ 
       Shares | ​ 
 ​ | ​      
 ​      
 Amount |   ​ 
   ​ | ​ 
 ​ 
 ​ 
 ​ | ​            
 Extension    
 deposits due 
 from         
 Sponsor      |        ​ | ​ 
 ​ 
 ​ 
 ​ | ​          
 ​          
 Additional 
 Paid-in    
 Capital    |       ​ 
       ​ | ​ 
 ​ 
 ​ 
 ​ | ​           
 ​           
 Accumulated 
 Deficit     |           ​ 
           ​ 
           ​ | ​ 
 ​ 
 ​ 
 ​ | ​             
 Total         
 Stockholders’ 
 Deficit       |           ​ 
           ​ |
|:----------------------------------------------------------------------|:--|-------------:|:--|:-------|----:|:--|:-------------|---------:|:--|:-----------|--------:|:--|:------------|------------:|:--|:--------------|------------:|
| Balance as of January 1, 2025                                         | ​ |    6,900,000 | ​ | $      | 690 | ​ | $            | -160,677 | ​ | $          |  51,795 | ​ | $           | -17,518,175